Where does Inis Biotech LLC rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Inis Biotech LLC ranks #17,779 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Inis Biotech LLC hold?

Inis Biotech LLC holds 16 US utility patents granted between 2015 and 2023, spanning 17 technology areas.

What is Inis Biotech LLC's Innovation Score?

Inis Biotech LLC has an Innovation Score of 30.9 out of 100 (36th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Inis Biotech LLC focus on?

Inis Biotech LLC's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 9 patents, ranking #2,057 of 6,058 assignees active in that subclass. Grants appear in 17 CPC subclasses total.

Is Inis Biotech LLC's patent grant rate increasing or decreasing?

Inis Biotech LLC's recent grant velocity is -67% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Inis Biotech LLC's patents?

Inis Biotech LLC's patents average 9.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Inis Biotech LLC patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Inis Biotech LLC

USPTO PatentsView assignee record - 16 granted patents across 17 technology areas, recorded in grant years 2015–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Inis ranks #17,779 of 49,997 tracked US assignees by granted-patent volume, with 16 patents across 17 technology areas.

#17,779
of 49,997 US assignees by volume: 36th percentile
by Innovation Score (30.9/100): 9.4
avg claims per patent: -67%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R17779 · US Corporation #17,779 · 16 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 16 grants
MID-PACK #17,779/49,997
PHOTO-FINISH Immunovaccine
CPC-FOCUS A61P · 17 areas
INNOV-THIN 30.9/100
CLAIMS-PAR 9.4 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -67% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Immunovaccine Technologies Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Inis’s 30.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.8 pts (32%) Velocity 0.8 pts (3%) Breadth 14.6 pts (47%) Claim depth 5.7 pts (18%)

Qualcomm Incorporated · highest

85
Inis Biotech · this assignee

31
3D Lighting… · lowest

7

What this shows Inis's Innovation Score is 30.9/100 (36th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Inis?

Each dot is one of Inis’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Inis’s own 9.4 claims/patent is at or below the 12.7 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Inis vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Inis's grants concentrate

Inis Biotech LLC is a focused PatentsView assignee: 17 CPC subclasses with 56.3% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2019 (5 grants) versus a trough of 1 in 2016. By volume, Inis sits between Immunovaccine Technologies Inc. and Intermetallics Co., Ltd..

Inis's three-year grant acceleration

Inis Biotech LLC shows 1 grants in 2022–2024 against only 8 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Immunovaccine

16
Industry Academic…

16
Infastech Intelle…

16
INI Power Systems

16
Inkbed

16
Insectergy

16
Institut Regional…

16
Intermetallics

16
Inis Biotech ◀

16

What this shows Inis holds 16 patents at rank #17,772, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Inis

By rank, the assignees closest to #17,772 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Inis's primary technology class.

Inis's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

31 36th percentile higher than 36% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Inis Biotech LLC patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	12.5%
2016	1	6.3%
2017	3	18.8%
2018	1	6.3%
2019	5	31.3%
2020	1	6.3%
2021	2	12.5%
2023	1	6.3%

Which technologies does Inis Biotech LLC patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 9

C07K - Peptides 8

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 8

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 5

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

C22B - Production AND Refining OF Metals ; Pretreatment OF RAW Materials 2

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 2

C12R - Indexing Scheme Associated With Subclasses C12c - C12q, Relating TO Microorganisms 1

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 1

C07J - Steroids 1

G01T - Measurement OF Nuclear OR X-radiation 1

B09B - Disposal OF Solid Waste NOT Otherwise Provided FOR 1

Y02W - Climate Change Mitigation Technologies Related TO Wastewater Treatment OR Waste Management 1

H01M - Processes OR Means, e.g. Batteries, FOR THE Direct Conversion OF Chemical Energy Into Electrical Energy 1

C07C - Acyclic OR Carbocyclic Compounds 1

Top 15 of 17 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Inis Biotech LLC's patent record in context - here's where to go next.

Inis Biotech LLC's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 56.3% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #17,779 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Inis Biotech LLC against Immunovaccine Technologies Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 30.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.